Stoke Therapeutics Inc - Asset Resilience Ratio
Stoke Therapeutics Inc (STOK) has an Asset Resilience Ratio of 46.40% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Stoke Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Stoke Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see STOK asset base.
Liquid Assets Composition Over Time
This chart breaks down Stoke Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore STOK long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $182.81 Million | 46.4% |
| Total Liquid Assets | $182.81 Million | 46.40% |
Asset Resilience Insights
- Very High Liquidity: Stoke Therapeutics Inc maintains exceptional liquid asset reserves at 46.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Stoke Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Stoke Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Stoke Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 47.90% | $200.45 Million | $418.43 Million | +15.16pp |
| 2024-12-31 | 32.74% | $88.92 Million | $271.56 Million | +28.38pp |
| 2023-12-31 | 4.36% | $9.95 Million | $228.34 Million | -40.96pp |
| 2022-12-31 | 45.32% | $116.04 Million | $256.07 Million | +13.95pp |
| 2021-12-31 | 31.36% | $74.92 Million | $238.87 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $297.93 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $107.54 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $2.44 Million | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more